Velia is a biotech company focused on the discovery and development of therapeutic applications for a previously overlooked class of human proteins. By translating novel biological insights into targeted treatments, Velia aims to address unmet medical needs in various therapeutic areas.
Funding
$55.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many potential therapeutic targets within the human proteome remain unexplored, hindering the development of novel treatments for various diseases. A lack of understanding of these proteins limits the ability to address unmet medical needs effectively.
Solution
Velia is a biotechnology company dedicated to identifying and developing therapeutic applications for a previously uncharacterized class of human proteins. By focusing on this overlooked area of biology, Velia aims to translate novel insights into targeted therapies. The company's approach involves rigorous scientific investigation to understand the function and therapeutic potential of these proteins. This knowledge is then leveraged to create innovative treatments for a range of diseases. Velia's goal is to address unmet medical needs by targeting previously inaccessible biological pathways.
Target Audience
Velia's primary focus is on patients with unmet medical needs across various therapeutic areas, as well as pharmaceutical companies seeking novel drug targets and therapeutic strategies.
Features
- Focus on a novel and previously uncharacterized class of human proteins.
- Translation of biological insights into targeted therapeutics.
- Discovery and development of treatments for various therapeutic areas.